Search Result

Results for "

CNS disease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Amyloid-β (3) Apoptosis (5) Aquaporin (2) Bcr-Abl (1) Beta-secretase (1) c-Fms (5) Cadherin (1) Calcium Channel (5) Cannabinoid Receptor (1) Caspase (3) Cathepsin (1) Cholinesterase (ChE) (2) Collagen (1) COMT (1) COX (2) Cytochrome P450 (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (4) Dopamine Receptor (5) Drug Isomer (1) Drug Metabolite (4) DYRK (2) Endogenous Metabolite (7) Environmental Pollutants (1) Epigenetic Reader Domain (1) ERK (1) Eukaryotic Initiation Factor (eIF) (1) Fluorescent Dye (1) FXR (1) GABA Receptor (2) Glycosidase (1) GSK-3 (2) HDAC (5) Histamine Receptor (1) iGluR (7) Interleukin Related (3) IPK Superfamily (1) Isotope-Labeled Compounds (1) LIM Kinase (LIMK) (1) Liposome (1) LRRK2 (1) mAChR (4) MAP4K (1) MARCKS (2) mGluR (4) Mitochondrial Metabolism (1) Monoamine Oxidase (1) mTOR (2) nAChR (3) NF-κB (1) Ninjurin (1) NO Synthase (3) NOD-like Receptor (NLR) (2) Opioid Receptor (3) P2X Receptor (2) Phosphodiesterase (PDE) (1) Potassium Channel (2) Raf (1) Reference Standards (9) SARS-CoV (4) Sodium Channel (2) Tau Protein (1) TGF-β Receptor (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) TRP Channel (1) Vasopressin Receptor (2) VEGFR (2) α-synuclein (1) γ-secretase (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (4) Infection (7) Inflammation/Immunology (13) Metabolic Disease (6) Neurological Disease (88)
Oligonucleotides:	Fillers (1)

102

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-Y0966

Glycine 10+ Cited Publications	Environmental Pollutants Endogenous Metabolite iGluR VEGFR Ninjurin	Infection Neurological Disease Inflammation/Immunology Cancer
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine inhibits the membrane aggregation of NINJ1 and prevents plasma membrane rupture during cell death. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

HY-12768

Sotuletinib 35+ Cited Publications BLZ945	c-Fms	Infection Neurological Disease Cancer
Sotuletinib (BLZ945) is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC₅₀ of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib can be used for microglia depletion, and for tumor and CNS-related disease research .

HY-P1240

MOG (35-55) mouse, rat Maximum Cited Publications 9 Publications Verification Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
MOG (35-55) mouse, rat (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) is a minor component of CNS myelin. MOG (35-55) mouse, rat has encephalitogenic activity and induces T cell proliferative. MOG (35-55) mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) mouse, rat (MOG (35-55)) can be used for experimental autoimmune encephalomyelitis (EAE) modeling .

HY-N2332A

Methyllycaconitine citrate Maximum Cited Publications 43 Publications Verification MLA citrate	nAChR	Neurological Disease
Methyllycaconitine (MLA) citrate is a potent, selective, CNS-penetrant, competitive α7nAChR antagonist. Methyllycaconitine citrate alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. Methyllycaconitine citrate prevents methamphetamine-induced effects in mouse striatum. Methyllycaconitine citrate can be used for neurological disease research, such as Alzheimer’s disease .

HY-103586

GS-441524 25+ Cited Publications	DNA/RNA Synthesis SARS-CoV	Infection
GS-441524 is a potent, orally active and CNS-penetrant viral RNA-dependent RNA polymerase inhibitor. GS-441524 competes with natural nucleosides to block viral RNA transcription as an alternative substrate and RNA chain terminator. GS-441524 inhibits the replication of feline infectious peritonitis virus, African swine fever virus, and severe acute respiratory syndrome coronavirus 2. GS-441524 reduces viral RNA levels in cats. GS-441524 can be used in research related to feline infectious peritonitis, African swine fever, and coronavirus disease 2019 (COVID-19) .

HY-12768A

Sotuletinib hydrochloride 35+ Cited Publications BLZ945 hydrochloride	c-Fms	Cancer
Sotuletinib (BLZ945) hydrochloride is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC₅₀ of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib hydrochloride can be used for microglia depletion, and for tumor and CNS-related disease research. .

HY-126358

Acetylcarnitine	Endogenous Metabolite Mitochondrial Metabolism	Neurological Disease Metabolic Disease Cancer
Acetylcarnitine is a CNS-penetrant endogenous metabolite. Acetylcarnitine shuttling links mitochondrial metabolism to histone acetylation and lipogenesis. Acetylcarnitine attenuates oxidative stress and neuroinflammation. Acetylcarnitine can be used for fatigue-associated diseases research. Acetylcarnitine can be used as a candidate diagnostic and prognostic biomarker of hepatocellular carcinoma .

HY-111263

NIAD-4 1 Publications Verification	Fluorescent Dye Amyloid-β	Others
NIAD-4 is a blood-brain barrier permeable fluorophore for optical imaging of amyloid-β (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (K_i) of 10 nM .

HY-156438

Ruvonoflast NT-0796	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease
Ruvonoflast (NT-0796) is an orally active, selective and CNS-penetrant NLRP3 inflammasome inhibitor. Ruvonoflast inhibits IL-1β release in human PBMC cells with an IC₅₀ value of 0.32 nM. Ruvonoflast is an isopropyl ester that undergoes intracellular conversion to Ruvonoflast, the carboxylic acid active species. Ruvonoflast reverses high fat diet-induced obesity, systemic inflammation and astrogliosis in the diet-induced obesity mouse model. Ruvonoflast is promising for research of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis .

HY-Y0966R

Glycine (Standard) 1 Publications Verification	Reference Standards Endogenous Metabolite iGluR VEGFR	Neurological Disease
Glycine (Standard) is the analytical standard of Glycine. This product is intended for research and analytical applications. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

HY-130795

GSK-3β inhibitor 2 1 Publications Verification	GSK-3	Neurological Disease
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active GSK-3β inhibitor with an IC₅₀ of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease .

HY-P1240A

MOG (35-55) TFA Maximum Cited Publications 9 Publications Verification Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
MOG (35-55) (MOG (35-55)) TFA is a minor component of CNS myelin. MOG (35-55) (TFA) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (TFA) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (TFA) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (MOG (35-55)) TFA can be used for experimental autoimmune encephalomyelitis (EAE) modeling .

HY-P1333

Dynorphin A 1 Publications Verification	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-B0061

Tandospirone citrate 3 Publications Verification SM-3997 citrate	5-HT Receptor	Neurological Disease Metabolic Disease
Tandospirone (SM-3997) citrate is a potent and selective 5-HT_1A receptor partial agonist, with a K_i of 27 nM. Tandospirone citrate has anxiolytic and antidepressant activities. Tandospirone citrate can be used for the research of the central nervous system disorders and the underlying mechanisms .

HY-13593

Chlorambucil 4 Publications Verification CB-1348; WR-139013	DNA Alkylator/Crosslinker	Neurological Disease Cancer
Chlorambucil (CB-1348), an orally active antineoplastic agent, is a CNS-penetrant bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .

HY-149555

DNL343	Eukaryotic Initiation Factor (eIF)	Neurological Disease
DNL343 is a potent, selective, orally active and brain-penetrant activator of eukaryotic initiation factor eIF2B. DNL343 inhibits the activity of the integrated stress response (ISR) in the central nervous system (CNS) and reverses neurodegeneration and neuroinflammation. DNL343 also prevents motor dysfunction and premature death in eIF2B loss-of-function (LOF) mutant mice. DNL343 can be used in the study of neurodegenerative diseases .

HY-W003969

Aminopicoline Ascensil; 2-Amino-4-methylpyridine	NO Synthase	Inflammation/Immunology
Aminopicoline (Ascensil) is a potent and non-selective inhibitor of nitric oxide synthase (NOS) isoenzymes (iNOS, nNOS, eNOS). Aminopicoline competes with arginine at the substrate-binding site of nitric oxide synthase, reduces cellular nitric oxide production, inhibits the elevation of plasma nitrate, increases mean arterial pressure at high doses, and also serves as a basis for radiolabeled ligands to localize nitric oxide synthase binding sites. Aminopicoline can be used in the research of diseases associated with septic shock, joint inflammation, intestinal inflammation, and *CNS* inflammation .

HY-14558

Tandospirone 3 Publications Verification SM-3997	5-HT Receptor	Neurological Disease
Tandospirone (SM-3997) is a potent and selective 5-HT_1A receptor partial agonist, with a K_i of 27 nM. Tandospirone has anxiolytic and antidepressant activities. Tandospirone can be used for the research of the central nervous system disorders and the underlying mechanisms .

HY-12345

ML365 5+ Cited Publications	Potassium Channel	Cardiovascular Disease
ML365 is a selective two-pore domain potassium channel KCNK3/TASK1 inhibitor, with an IC₅₀ of 4 nM. ML365 acts as a pharmacological tool that can be used to examine the specific roles of TASK1 channels .

HY-12150

CCMI 1 Publications Verification AVL-3288; UCI-4083	nAChR	Neurological Disease
CCMI (AVL-3288) is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs. CCMI has potential in CNS diseases with cognitive dysfunction .

HY-103309

ML218 2 Publications Verification	Calcium Channel	Neurological Disease
ML218 is a potent, selective and orally active T-type Ca ²⁺ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, K_ATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

HY-132806

Alogabat RG-7816; RO-7017773	GABA Receptor	Neurological Disease
Alogabat is a positive allosteric modulator (PAM) and agonist (K_i <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction .

HY-116016

Etilevodopa L-DOPA ethyl ester; Levodopa ethyl ester	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-156585

CNS-11	Tau Protein α-synuclein	Neurological Disease
CNS-11 is a brain-penetrant tau fibril-degrading compound. CNS-11 reduces α-synuclein. CNS-11 can be used in Alzheimer's and Parkinson's disease research .

HY-W019710

(E,E)-RGFP966	HDAC	Neurological Disease
(E,E)-RGFP966 is a selective and CNS permeable HDAC3 inhibitor that can be used for the research of Huntington’s disease .

HY-119943

PF-06256142 1 Publications Verification	Dopamine Receptor	Neurological Disease
PF-06256142 is a potent, selective, CNS-penetrant and orally active agonist of the D1 receptor, with an EC₅₀ and K_i of 33 nM and 12 nM, respectively. PF-06256142 has the potential for the research of schizophrenia and Parkinson's disease .

HY-147405

Tinlorafenib PF-07284890; ARRY-461	Raf ERK	Cancer
Tinlorafenib (PF-07284890) is the orally active inhibitor for BRAF and CRAF with IC₅₀s of 5.8 nM and 4.1 nM. Tinlorafenib (Compound 10) inhibits V600E mutated BRAF and V600K mutanted BRAF with IC₅₀s of 4.25 nM and 2.7 nM. Tinlorafenib can cross the blood brain barrier. Tinlorafenib demonstrates CNS penetration and can be used in the research of BRAF-associated malignant and benign tumors of the CNS as well as extracranial malignancies .

HY-159838

Enrupatinib EI‐1071	c-Fms Amyloid-β	Neurological Disease Cancer
Enrupatinib (EI‐1071) is a potent, orally active, CNS-penetrant and selective CSF1R inhibitor. Enrupatinib inhibits macrophage proliferation and osteoclast differentiation in vitro. Enrupatinib preserves microglia distal to Aβ plaques. Enrupatinib mitigates Alzheimer's disease (AD)-related pathologies by reducing neuroinflammation, preserving neuronal integrity, lowering disease-associated microglia gene expression, and enhancing cognitive function in 5xFAD and J20 mouse models. Enrupatinib reduces tumor-associated macrophage infiltration and enhances antitumor activity of anti-PD-1 antibody in murine colorectal cancer and breast cancer models. Enrupatinib can be used for the research of AD, colorectal cancer, and breast cancer .

HY-124832

δ-Secretase inhibitor 11 1 Publications Verification	Caspase Amyloid-β	Neurological Disease
δ-Secretase inhibitor 11 (compound 11) is an orally active, potent, BBB-penetrated, non-toxic, selective and specific δ-secretase inhibitor, with an IC₅₀ of 0.7 μM. δ-Secretase inhibitor 11 interacts with both the active site and allosteric site of δ-secretase. δ-Secretase inhibitor 11 attenuates tau and APP (amyloid precursor protein) cleavage. δ-Secretase inhibitor 11 ameliorates synaptic dysfunction and cognitive impairments in tau P301S and 5XFAD transgenic mouse models. δ-Secretase inhibitor 11 can be used for Alzheimer's disease research .

HY-14418

VU0361737 ML-128	mGluR	Neurological Disease
VU0361737 (ML-128) is a potent, selective and CNS penetrant positive allosteric modulator of metabotropic glutamate receptor 4 (mGluR₄ PAM), with EC₅₀s of 240 nM and 110 nM for human and rat mGluR₄ receptors, respectively. VU0361737 has neuroprotective effect. VU0361737 is potential for Parkinson's disease research .

HY-115498

ARN14494	Apoptosis NO Synthase Interleukin Related COX	Neurological Disease Inflammation/Immunology
ARN14494 is a potent and selective serine palmitoyltransferase (SPT) inhibitor, with an IC₅₀ of 27.3 nM. ARN14494 affects the CNS in terms of anti-inflammation and neuroprotection. ARN14494 protects neurons from β-amyloid 1-42-induced neurotoxicity through a variety of mechanisms, including anti-oxidation, anti-apoptosis, and anti-inflammation. ARN14494 can be used for Alzheimer’s disease research .

HY-125339

Ro 41-0960	COMT Apoptosis	Neurological Disease Cancer
Ro 41-0960 is a CNS-penetrant, orally active catechol-O-methyl transferase (COMT) inhibitor. Ro 41-0960 reduces dopamine catabolism, increases striatal dopamine and DOPAC levels, decreases striatal HVA levels, induces apoptosis, inhibits proliferation and extracellular matrix formation in uterine fibroid cells. Ro 41-0960 arrests or shrinks uterine fibroid lesions in rats. Ro 41-0960 can be used for the research of Parkinson’s disease, uterine leiomyomas, and breast cancer .

HY-105685

SRX246	Vasopressin Receptor	Cardiovascular Disease Neurological Disease
SRX246 is a potent, BBB-penetrant, highly selective vasopressin 1a (V1a) receptor antagonist (K_i=0.3 nM for human V1a). SRX246 has no interaction at V1b and V2 receptors. SRX246 also displays negligible binding at 64 others receptors classes, including 35 G-proteincoupled receptors. SRX246 can be used for treatment of stress-related disorders .

HY-172118

SGC-CDKL5/GSK3	GSK-3	Neurological Disease
CDKL5/GSK3-IN-1 (Compound 2) is a potent and selectivity chemical probe for CDKL5/GSK3.CDKL5/GSK3-IN-1 has potent inhibition of CDKL5 and GSK3α/β, with IC₅₀ values of 4.6, 24 and 9.5 nM for CDKL5, GSK3β and GSK3α, respectively, in the NanoBRET assay. CDKL5/GSK3-IN-1 can be used for the research of CNS diseases .

HY-132981

Lu AF27139	P2X Receptor	Neurological Disease
Lu AF27139 is a potent, selective, and orally active antagonist of P2X7 receptor (IC₅₀s of 12 and 2.4 nM for human and rat, K_is of 22, 54, and 13 nM for mouse, human, and rat, respectively). Lu AF27139 has rodent-active and CNS-penetrant character. Lu AF27139 has the potential for the research of CNS diseases .

HY-113616A

VU0364572 TFA	MARCKS mAChR	Neurological Disease
VU0364572 TFA is an orally active and selective allosteric agonist of the M1 muscarinic receptor with an EC₅₀ of 0.11 μM. VU0364572 TFA has neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer’s Disease. VU0364572 TFA is CNS penetrant .

HY-103586A

GS-441524 hydrochloride 25+ Cited Publications	DNA/RNA Synthesis SARS-CoV	Infection
GS-441524 hydrochloride is a potent, orally active and CNS-penetrant viral RNA-dependent RNA polymerase inhibitor. GS-441524 hydrochloride competes with natural nucleosides to block viral RNA transcription as an alternative substrate and RNA chain terminator. GS-441524 hydrochloride inhibits the replication of feline infectious peritonitis virus, African swine fever virus, and severe acute respiratory syndrome coronavirus 2. GS-441524 hydrochloride reduces viral RNA levels in cats. GS-441524 hydrochloride can be used in research related to feline infectious peritonitis, African swine fever, and coronavirus disease 2019 (COVID-19) .

HY-148624

CHDI-00484077	HDAC	Neurological Disease
CHDI-00484077 (Compound 12) is a CNS-penetrant class IIa HDAC inhibitor, with IC₅₀s of 0.01 μM (HDAC4), 0.02 μM(HDAC5), 0.02 μM (HDAC7), 0.03 μM (HDAC9) respectively. CHDI-00484077 can be used for research of huntington’s disease .

HY-116016A

Etilevodopa hydrochloride L-DOPA ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-W001601

Budipine	iGluR	Neurological Disease
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .

HY-145887

BCR-ABL1-IN-1	Bcr-Abl	Cancer
BCR-ABL1-IN-1 (Example 74) is the inhibitor for ABL1 (64-515) with IC₅₀ of 8.7 nM. BCR-ABL1-IN-1 can be used in research on diseases related to the central nervous system (CNS) .

HY-155058

Nav1.3 channel inhibitor 1	Sodium Channel	Neurological Disease
Nav1.3 channel inhibitor 1 (compound 15b) is a state-dependent voltage-gated sodium channel Na_v1.3 inhibitor (IC₅₀=20 nM). Nav1.3 channel inhibitor 1 can penetrate the blood-brain barrier and can be used in the research of nervous system diseases .

HY-110053

Tandospirone hydrochloride SM-3997 hydrochloride	5-HT Receptor	Neurological Disease
Tandospirone (SM-3997) hydrochloride is a potent and selective 5-HT_1A receptor partial agonist, with a K_i of 27 nM. Tandospirone hydrochloride has anxiolytic and antidepressant activities. Tandospirone hydrochloride can be used for the research of the central nervous system disorders and the underlying mechanisms .

HY-144764

5-HT1A antagonist 1	5-HT Receptor	Neurological Disease
5-HT1A antagonist 1 (compound 6f) is a potent and selective antagonist of 5-HT_1A receptor, with a K_i of 35 nM. 5-HT1A antagonist 1 can be used for the research of CNS diseases .

HY-146068

AEP-IN-1	Cathepsin	Neurological Disease
AEP-IN-1 (Compound 13e) is a CNS agent-like non-covalent inhibitor of asparagine endopeptidase (AEP), with the IC₅₀ of 89 nM. AEP-IN-1 can be used for the research of numerous neurological diseases such as Alzheimer’s disease (AD) .

HY-144074

LRRK2-IN-4	LRRK2	Neurological Disease
LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC₅₀ of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease .

HY-50707

(Rac)-TTA-P2 (Rac)-T-Type calcium channel inhibitor	Calcium Channel Drug Isomer	Neurological Disease
(Rac)-TTA-P2 is the isomer of TTA-P2 (HY-10035), and can be used as an experimental control. TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease .

HY-156986

ITH15004	P2X Receptor	Neurological Disease
ITH15004 is a CNS-penetrated P2X7 antagonist, used for the study of neurodegenerative diseases .

HY-109527

5-HT7 agonist 1	5-HT Receptor	Neurological Disease
5-HT7 agonist 1 is a selective 5-HT7 receptor agonist, with an IC₅₀ of 222.93 nM, can be used for the 5-HT7 receptor related disease, such as CNS disorders.

HY-113616

VU0364572	mAChR MARCKS	Neurological Disease
VU0364572 is a selective allosteric agonist of the M1 muscarinic receptor with an EC₅₀ of 0.11 μM. VU0364572 has neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer’s Disease. VU0364572 is orally active and is CNS penetrant .

Cat. No.	Product Name

HY-L920

CNS MPO Lead-like Library

24,816 compounds

With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. The CNS MPO (Multi-Parameter Optimization) score is a widely recognized algorithm in medicinal chemistry. Developed by Pfizer, this method is based on an analysis of approved CNS drugs and their interior CNS drug candidates, establishing the CNS MPO rules. It incorporates six key physicochemical properties (ClogP, ClogD, MW, TPSA, HBD, and pKa) to prospectively optimize CNS drug attributes—such as high blood-brain barrier (BBB) permeability, low P-gp efflux liability, low metabolic clearance, and high safety—thereby improving the clinical success rate of CNS drug candidates. The CNS MPO compound library is a collection of compounds with CNS MPO scores greater than 5, specifically designed for CNS drug discovery.

HY-L028

CNS-Penetrant Compound Library

1,096 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 1,096 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L919

MCE CNS BBB Lead-like Library

27,503 compounds

With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

HY-L0123V

Life Chemicals CNS Focused Screening Library

30,300 compounds

The incidence and significance of central nervous system diseases are increasing at an alarming rate all over the world. Although substantial research efforts have been applied to develop new CNS-active drugs, only a few CNS disorders are addressed satisfactorily, while the remaining ones pose significant clinical challenges. Blood-brain barrier (BBB) permeability is one of the most important limiting factors in the design and development of novel CNS-targeted pharmaceuticals for the treatment of neurological disorders.

Carefully selected from the HTS Compound Collection to meet the parameters optimized for high BBB-permeability, our CNS Focused Screening Library comprising over 30,300 structurally-diverse and potentially CNS-active screening compounds. This original Screening Compound Library is aimed at supporting CNS drug design projects and HTS efforts in search for novel neurotherapeutics.

HY-L013

Neuronal Signaling Compound Library

3,802 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 3,802 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

HY-L070

Neuroprotective Compound Library

1,748 compounds

Neurodegenerative diseases are characterised by progressive dysfunction and death of neurons, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). Neuroprotection is an approach to preserve neurons so that neurons cannot be hurt by different pathological factors in neurodegenerative diseases. Neuroprotectors are some agonists and antagonists targeting some key targets in neuroprotactive signal pathways, such as calcium and sodium channel blockers, GABA receptor agonists, NMDA receptor Antagonists, etc. Current neuroprotectors cannot reverse existing damage, but they may protect against further nerve damage and slow down any degeneration of the central nervous system (CNS) and still play important roles in the treatment of neurodegenerative diseases.

MCE offers a unique collection of 1,748 compounds with potential neuroprotective activities. These compounds mainly act on some key targets in neuroprotetive signal pathways, such as calcium channel, sodium channel, adenosine A1 receptor, etc. MCE Neuroprotective Compopund Library is a useful tool in neuroprotective drug discovery.

Cat. No.	Product Name	Type

HY-111263

NIAD-4 1 Publications Verification	Fluorescent Dyes
NIAD-4 is a blood-brain barrier permeable fluorophore for optical imaging of amyloid-β (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (K_i) of 10 nM .

Cat. No.	Product Name	Target	Research Area

HY-P1240

MOG (35-55) mouse, rat Maximum Cited Publications 9 Publications Verification Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
MOG (35-55) mouse, rat (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) is a minor component of CNS myelin. MOG (35-55) mouse, rat has encephalitogenic activity and induces T cell proliferative. MOG (35-55) mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) mouse, rat (MOG (35-55)) can be used for experimental autoimmune encephalomyelitis (EAE) modeling .

HY-P1240A

MOG (35-55) TFA Maximum Cited Publications 9 Publications Verification Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
MOG (35-55) (MOG (35-55)) TFA is a minor component of CNS myelin. MOG (35-55) (TFA) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (TFA) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (TFA) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (MOG (35-55)) TFA can be used for experimental autoimmune encephalomyelitis (EAE) modeling .

HY-P1333

Dynorphin A 1 Publications Verification	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-P1240B

MOG (35-55) acetate Maximum Cited Publications 9 Publications Verification Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate	Peptides	Neurological Disease Inflammation/Immunology
MOG (35-55) (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) acetate is a minor component of CNS myelin. MOG (35-55) (acetate) has encephalitogenic activity and induces T cell proliferative. MOG (35-55) (acetate) induces Th1 cytokine response as well as relatively high levels of IgG antibodies. MOG (35-55) (acetate) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. MOG (35-55) (Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat) acetate can be used for experimental autoimmune encephalomyelitis (EAE) modeling .

HY-P5462

PLP (180-199)	Peptides	Inflammation/Immunology
PLP (180-199) is a biological active peptide. (This is amino acids 180-199 fragment of myelin proteolipid protein (PLP). PLP, the most abundant myelin protein of the central nervous system, has been used in multiple sclerosis (MS) studies. MS is a chronic inflammatory demyelinating disease of the CNS.)

HY-P10937

AQP4 (205-215)	Aquaporin	Inflammation/Immunology
AQP4 (205-215) is a fragment of Aquaporin-4 (AQP4). AQP4 is a neuromyelitis optica autoantigen that is upregulated and presented in B cells after engagement of CD40. AQP4 is associated with autoimmune inflammatory diseases of the central nervous system (CNS), neuromyelitis optica (NMO) .

HY-P10937A

AQP4 (205-215) TFA	Aquaporin	Inflammation/Immunology
AQP4 (205-215) TFA is a fragment of Aquaporin-4 (AQP4). AQP4 is a neuromyelitis optica autoantigen that is upregulated and presented in B cells after engagement of CD40. AQP4 is associated with autoimmune inflammatory diseases of the central nervous system (CNS), neuromyelitis optica (NMO) .

HY-P1333A

Dynorphin A TFA	Opioid Receptor Apoptosis Caspase Endogenous Metabolite	Neurological Disease
Dynorphin A TFA is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A TFA is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A TFA can induce neuronal death, and can be used in the research of neurological disease .

HY-P1625

Daeatal Dynorphin A ethylamide (1-9)	Opioid Receptor	Neurological Disease
Daeatal (Dynorphin A ethylamide (1-9)) is an ethylamine-modified dynorphin fragment that can be used in the study of analgesia, addiction, depression, etc. Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .

HY-P11133

Leukokinin 1	Peptides	Neurological Disease
Leukokinin 1 is a member of the leucokinin peptide family. Leukokinin 1 operates by binding to and activating specific G-protein-coupled receptors (GPCRs). Leukokinin 1 plays a wide role in the central nervous system (CNS) of molluscs. Leukokinin 1 can be used for research on neurological disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-Y0966

Glycine 10+ Cited Publications	Structural Classification Neurological Disease Classification of Application Fields Amino acids Endogenous metabolite Disease Research Fields Source Classification	Environmental Pollutants Endogenous Metabolite iGluR VEGFR Ninjurin
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine inhibits the membrane aggregation of NINJ1 and prevents plasma membrane rupture during cell death. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

HY-126358

Acetylcarnitine	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Mitochondrial Metabolism
Acetylcarnitine is a CNS-penetrant endogenous metabolite. Acetylcarnitine shuttling links mitochondrial metabolism to histone acetylation and lipogenesis. Acetylcarnitine attenuates oxidative stress and neuroinflammation. Acetylcarnitine can be used for fatigue-associated diseases research. Acetylcarnitine can be used as a candidate diagnostic and prognostic biomarker of hepatocellular carcinoma .

HY-Y0966R

Glycine (Standard) 1 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Endogenous metabolite Cancer Source Classification	Reference Standards Endogenous Metabolite iGluR VEGFR
Glycine (Standard) is the analytical standard of Glycine. This product is intended for research and analytical applications. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

HY-N2332

Methyllycaconitine MLA	Structural Classification Alkaloids Piperidine Alkaloids Ranunculaceae Delphinium ajacis Plants Source Classification	nAChR
Methyllycaconitine (MLA) is a potent, selective, CNS-penetrant, competitive α7nAChR antagonist. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum. Methyllycaconitine can be used for neurological disease research, such as Alzheimer’s disease .

HY-N17383

Ligusticum cycloprolactam	Structural Classification Natural Products Umbelliferae Plants Echinacea angustifolia DC. Source Classification	Toll-like Receptor (TLR) NF-κB Collagen Interleukin Related Cadherin NOD-like Receptor (NLR) TGF-β Receptor FXR Apoptosis
Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease .

Cat. No.	Product Name	Chemical Structure

HY-103586S2

GS-441524-d

GS-441524-d is the deuterium labeled GS-441524 (HY-103586). GS-441524 is a potent, orally active and CNS-penetrant viral RNA-dependent RNA polymerase inhibitor. GS-441524 competes with natural nucleosides to block viral RNA transcription as an alternative substrate and RNA chain terminator. GS-441524 inhibits the replication of feline infectious peritonitis virus, African swine fever virus, and severe acute respiratory syndrome coronavirus 2. GS-441524 reduces viral RNA levels in cats. GS-441524 can be used in research related to feline infectious peritonitis, African swine fever, and coronavirus disease 2019 (COVID-19) .

Cat. No.	Product Name		Classification

HY-Y0966

Glycine 10+ Cited Publications		Fillers
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine inhibits the membrane aggregation of NINJ1 and prevents plasma membrane rupture during cell death. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CNS disease

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products